A global biopharmaceutical company, AbbVie develops and sells medicines for immune, nerve, and cancer conditions — brands include Skyrizi, Rinvoq, Humira, Botox, and Imbruvica — as well as cosmetic treatments like Botox Cosmetic and the Juvederm line. It was born in 2013 when Abbott Laboratories split, spinning off its drug business into a fresh company. Fun fact: the name blends "Abb" (from Abbott) with "Vie," echoing the Latin word for "life," and insiders noted it conveniently rhymes with "R&D."
AbbVie completes $10.0 billion multi-tranche senior notes offering to fund Apogee acquisition
On August 18, 2026, AbbVie completed an underwritten public offering of $10.0 billion aggregate principal amount of senior notes across nine tranches.
Show detailsHide details
The offering included $500 million floating rate notes due 2028 and fixed-rate notes ranging from $1.0 billion to $1.5 billion per tranche, with maturities from 2028 to 2066 and coupons from 4.500% to 6.100%.
Net proceeds will fund a portion of the cash consideration for AbbVie's acquisition of Apogee Therapeutics, Inc., plus related fees and expenses; any remainder for general corporate purposes.
If the Apogee acquisition is terminated before closing, AbbVie must redeem most notes (excluding 2056 and 2066 notes) at 101% of principal plus accrued interest.
The notes are unsecured, unsubordinated obligations ranking equally with AbbVie's other unsecured debt, and are governed by a supplemental indenture dated August 18, 2026.
The offering was registered under AbbVie's Form S-3ASR shelf registration statement and is reported under Item 8.01 as a material event not otherwise specified.
8.01 Other Events · 9.01 Financial Statements and Exhibits
AbbVie prices $10.0B multi-tranche senior notes offering to fund Apogee acquisition
On August 4, 2026, AbbVie entered into an underwriting agreement with Morgan Stanley, BofA Securities, J.P. Morgan, and SG Americas to issue $10.0 billion aggregate principal amount of senior notes across nine tranches.
Show detailsHide details
The offering includes floating rate notes due 2028 and fixed-rate notes with coupons ranging from 4.500% to 6.100% and maturities from 2028 to 2066.
The public offering prices range from 99.410% to 100% of principal amount, with net proceeds expected to be approximately $9.93 billion.
AbbVie intends to use the net proceeds to fund a portion of its cash payment obligations in connection with its acquisition of Apogee Therapeutics and for general corporate purposes, including debt repayment or repurchase.
The closing of the sale is expected on August 18, 2026, and the notes are registered under AbbVie's Form S-3ASR registration statement.
The underwriting agreement includes customary representations, warranties, indemnification, and contribution provisions.
8.01 Other Events · 9.01 Financial Statements and Exhibits
AbbVie reports Q2 2026 net revenues of $16.990B, up 10.2%; adjusted EPS $3.65, up 22.9%.
Second-quarter diluted EPS was $2.03 on a GAAP basis, up 290.4%; adjusted diluted EPS was $3.65, up 22.9%, including a $0.17 per share unfavorable impact from acquired IPR&D and milestones expense.
Show detailsHide details
Worldwide net revenues were $16.990 billion, up 10.2% reported or 9.5% operational; immunology portfolio revenues were $8.786 billion, up 15.1% reported.
Neuroscience portfolio revenues were $3.228 billion, up 20.3% reported; oncology revenues were $1.650 billion, down 1.5% reported; aesthetics revenues were $1.282 billion, up 0.3% reported.
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion equity value, expected to close in Q3 2026.
Full-year 2026 adjusted diluted EPS guidance updated from $13.91-$14.11 to $13.87-$14.07, including a $0.14 dilutive impact from the Apogee acquisition.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
AbbVie expects Q2 2026 GAAP and adjusted non-GAAP EPS to include a $0.17 unfavorable impact from $291 million pre-tax acquired IPR&D and milestones expense.
Show detailsHide details
Q2 2026 adjusted diluted EPS guidance is $3.57-$3.61, including the acquired IPR&D expense.
Full-year 2026 adjusted diluted EPS guidance is $13.91-$14.11, including the Q2 expense.
Previously announced 2026 guidance excluded acquired IPR&D and milestones expense beyond Q1 2026.
Q2 2026 results are preliminary and subject to financial statement closing procedures.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, ~$10.9B total equity value
The transaction values Apogee at approximately $10.9 billion total equity value and is expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory approvals.
Show detailsHide details
AbbVie and Apogee announced a definitive agreement on June 22, 2026, for AbbVie to acquire all outstanding Apogee shares at $135.11 per share in cash.
Apogee's lead asset, zumilokibart (APG777), is a late-stage anti-IL-13 monoclonal antibody for atopic dermatitis; the pipeline also includes APG273 for asthma.
The acquisition is expected to be accretive to AbbVie's adjusted diluted EPS beginning in 2032.
Fairmount Funds Management LLC and Venrock Associates have entered into voting agreements supporting the transaction.
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
AbbVie stockholders elect four Class II directors and ratify Ernst & Young as auditor at 2026 annual meeting.
Stockholders elected Jennifer L. Davis, Melody B. Meyer, Robert A. Michael, and Frederick H. Waddell as Class II directors with terms expiring in 2029.
Show detailsHide details
AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026.
Stockholders ratified the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2026.
Stockholders approved, on an advisory basis, the compensation of AbbVie's named executive officers.
Stockholders did not approve a management proposal to eliminate supermajority voting or a stockholder proposal to require an independent chair.
5.07 Submission of Matters to a Vote of Security Holders
AbbVie updates 2026 EPS guidance for $744M acquired IPR&D expense
AbbVie expects first-quarter 2026 GAAP and adjusted non-GAAP earnings to include $744 million pre-tax acquired IPR&D and milestones expense, reducing diluted EPS by $0.41.
Show detailsHide details
First-quarter 2026 adjusted diluted EPS guidance is $2.56 to $2.60, including the impact of the expense.
Full-year 2026 adjusted diluted EPS guidance is $13.96 to $14.16, including the first-quarter expense.
The expense was excluded from prior 2026 guidance announced on February 4, 2026.
Results for the quarter ended March 31, 2026 are preliminary and subject to closing procedures.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits